Acalabrutinib 100mg tablets
NHS hospitals in England used £200,582,903 of indicative cost of Acalabrutinib 100mg tablets in the 12 months to July 2026, about 0.8% of all hospital medicines spend. That is up 5.4% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Acalabrutinib 100mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Acalabrutinib 100mg tablets most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Christie Nhs Foundation Trust | £6,243,143 |
| East Kent Hospitals University Nhs Ft | £4,562,291 |
| Univ Hpl B/Ham Nhs Foundation Trust | £4,026,795 |
| United Lincolnshire Hospitals Nhs Trust | £3,932,276 |
| University Hpls North Midlands Nhs Trust | £3,863,896 |
| University Hospitals Dorset Nhs Ft | £3,862,884 |
| South Tees Hosp Nhs Foundation Trust | £3,568,956 |
| Sheffield Teaching Hospitals Nhs Trust | £3,465,415 |
| Derby Teaching Hospitals Nhs Found Trust | £3,421,908 |
| Western Sussex Hospitals Nhs Found Trust | £3,402,093 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.